| For: | Abdelhamed W, Amin M, Waked I, El-Kassas M. Metabolic dysfunction-associated steatotic liver disease in Egypt: Epidemiology, risk factors and management challenges. World J Gastroenterol 2025; 31(45): 111643 [PMID: 41378328 DOI: 10.3748/wjg.v31.i45.111643] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v31/i45/111643.htm |
| Number | Citing Articles |
| 1 |
Amal Mohammed Dwidar, Ayat Ismail Ferra, Amany Mohammed Dwidar, Eslam Saber Esmail, Rania Mamdouh Elkafoury. Metabolic features’ effect on FibroScan-AST (FAST) score in Egyptian patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Egyptian Liver Journal 2026; 16(1) doi: 10.1186/s43066-025-00488-y
|
| 2 |
Mohamed El-Kassas, Gamal Esmat. Three decades of change: schistosomiasis, hepatitis C, and the rise of metabolic dysfunction-associated steatotic liver disease in Egypt. Arab Journal of Gastroenterology 2026; doi: 10.1016/j.ajg.2026.02.005
|
| 3 |
Xiao-Lin Liu, Jian-Gao Fan. Letter to the Editor: Prevention and management of metabolic dysfunction-associated steatotic liver disease: Insights from Egypt and implications for China. World Journal of Gastroenterology 2026; 32(32): 117644 doi: 10.3748/wjg.117644
|
| 4 |
Mohamed L. F. Abdelmeged, Ahmed S. Allam, Ahmed Elsayed Mohamed Kamal Elsayed, Amal S. M. Bakir, Samy M. A. Mahmoud. Association between metabolic associated fatty liver disease (MAFLD) and non-alcoholic fatty pancreatic disease (NAFPD) among Egyptian patients. Egyptian Liver Journal 2026; 16(1) doi: 10.1186/s43066-026-00531-6
|